AIC
BNTC icon

Ameritas Investment Company’s Benitec Biopharma BNTC Stock Holding History

Ameritas Investment Company’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-8
Closed -$3K – 1075
2018
Q4 		$3K Buy
+8
New +$4.42K ﹤0.01% 1309

Other funds holding BNTC

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameritas Investment Company's BNTC Position: Q1 2019 in Review

Ameritas Investment Company sold out of Benitec Biopharma (BNTC) in Q1 2019, closing a stake of 8 shares — an estimated $3K sold.

Ameritas Investment Company first reported a position in BNTC in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 6 funds tracked by Wall St. Rank hold BNTC as of Q1 2019.

  • Ameritas Investment Company reported no remaining Benitec Biopharma position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 8 Benitec Biopharma shares in Q1 2019, an estimated $3K.
  • Ameritas Investment Company first reported a position in Benitec Biopharma in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Benitec Biopharma position peaked at $3K in Q4 2018.
  • 6 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.